CClinicalTrials.gg
CompletedNCT03823742Updated Mar 24, 2026

Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?

An interventional study of Cognitive Behavioral Therapy and Low FODMAP Diet in Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome and Functional Gastrointestinal Disorders, sponsored by Baylor College of Medicine. Completed at 2 sites in United States. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
7 Years to 12 Years
Sex
All
01

Study summary

The purpose of this study is find out if we can use simple tests (biomarkers) to tell us if a specific child would benefit most from CBT or from the low FODMAPs diet.

Read the detailed description

AIM 1: We will categorize children ages 7-12 yrs. of age with FGIDs (n=250) as to whether they have/do not have one or more of the following abnormal physiologic changes: a) Autonomic Nervous System imbalance as indicated by low heart rate variability; and/or (b) Abnormalities in gut physiology: Impaired gut barrier function (increased permeability); and/or increased abundance of species of Gammaproteobacteria and/or Clostridia; and/or Gut neuroimmune dysfunction (increased fecal chromogranin A and secretogranin 2 concentrations).

AIM 2: Children will be randomized to the two treatments most commonly used in clinical practice: CBT or a low FODMAP diet for a 3-week treatment period. We will compare the response to the treatments in those with/without abnormal physiologic biomarkers at 3 weeks, 3 months, and 6 months.

02

Conditions studied

  • Irritable Bowel Syndrome
  • Functional Abdominal Pain Syndrome
  • Functional Gastrointestinal Disorders
  • Functional Bowel Disorder
  • Functional Abdominal Pain
  • Functional Abdominal Pain Disorders
03

In context

Irritable Bowel Syndrome

1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.

This study's enrollment of 163 is above the median of 71 across 853 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 734 studies on the registry; 110 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 44 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A child 7-12 years of age with a FGID will be recruited if the medical evaluation reveals no organic reason for the abdominal pain and the child has abdominal pain that meets the definition of a FGID (i.e., IBS, functional abdominal pain) according to the pediatric Rome III criteria (Rome IV will be substituted when validated). Parents and children must speak and understand English because of the psychological assessment and CBT requirements.

Exclusion criteria

Exclusion Criteria:

  • Children who have: had past bowel surgery; documented GI disorders (e.g., Crohn's disease); a serious chronic medical condition (e.g., diabetes); weight and/or height \< 2 SD for age; chronic conditions with GI symptoms (e.g., cystic fibrosis); autism spectrum disorder, significant developmental delay, psychosis, or a history of bipolar disorder; been treated with antibiotics/probiotics within 2 mo. (because of effects on gut microbiome analysis), and children who for some reason could not be randomized to the low FODMAP diet.Vegetarian; children who are currently on the FODMAP Diet or receiving CBT Children who speak only Spanish are not eligible because the Rome questionnaire and psychological testing are not available in Spanish. Despite this, a large proportion of the children enrolled will be Hispanic.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Cognitive Behavioral Therapy

    Cognitive Behavioral Therapy

    Other: Cognitive Behavioral Therapy

  • Experimental
    Low FODMAP diet

    Low FODMAP diet

    Other: Low FODMAP Diet

Interventions

  • OtherCognitive Behavioral Therapy

    Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .

  • OtherLow FODMAP Diet

    Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.

06

What researchers measure

Primary outcomes

  1. Symptom Improvement

    Abdominal pain frequency or severity

    Time frame: 3 to 4 weeks

Secondary outcomes

  1. Improvement in quality of life

    PedsQL or Functional Disability

    Time frame: 3 months

  2. Symptom Improvement

    Abdominal pain frequency or severity

    Time frame: 3 months

  3. Improvement in quality of life

    PedsQL or Functional Disability

    Time frame: 6 months

  4. Symptom Improvement

    Abdominal pain frequency or severity

    Time frame: 6 months

Other outcomes

  1. Improvement in quality of life

    PedsQL or Functional Disability

    Time frame: 3 to 4 weeks

07

Study locations

2 sites
  • Children's Nutrition Research Center
    Houston, Texas 77030, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03823742
Lead sponsor
Baylor College of Medicine
Collaborators
University of Washington
Responsible party
Robert Shulman, M.D. (Professor, Baylor College of Medicine) — Principal investigator
First posted
Jan 30, 2019
Start date
Feb 22, 2019
Primary completion
Dec 31, 2024
Completion
Dec 31, 2025
Last update
Mar 24, 2026

Study contacts

Robert J. Shulman, MD
principal investigator · Baylor College of Medicine
Rona Levy, PhD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion